GT Biopharma, Inc. (GTBP) |
|
0.5301 -0.034 (-6.03%)
|
03-22 10:46 |
|
Open: |
0.5444 |
Pre. Close: |
0.5641 |
|
High:
|
0.6499 |
Low:
|
0.5301 |
|
Volume:
|
7,894 |
Market Cap:
|
19(M) |
|
|
|
Technical analysis |
as of: 2023-03-22 10:46:24 AM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 0.8  One year: 0.96 |
| Support: |
Support1: 0.46 Support2: 0.39 |
| Resistance: |
Resistance1: 0.69 Resistance2: 0.82 |
| Pivot: |
0.6 |
| Moving Average: |
MA(5): 0.55  MA(20): 0.61
MA(100): 1.16 MA(250): 1.94 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 34.5 %D(3): 30.4 |
| RSI: |
RSI(14): 36.6 |
| 52-week: |
High: 3.28 Low: 0.46 |
| Average Vol(K): |
3-Month: 95 (K) 10-Days: 97 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ GTBP ] has closed above bottom band by 34.5%. Bollinger Bands are 44.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.6 - 0.6 |
0.6 - 0.61 |
|
Low:
|
0.52 - 0.53 |
0.53 - 0.53 |
|
Close:
|
0.56 - 0.56 |
0.56 - 0.57 |
|
Company Description |
|
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California. |
Headline News |
Tue, 21 Mar 2023
SRAX, INC. : Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
Wed, 15 Mar 2023
GT Biopharma Inc (GTBP) Stock Falls -9.23% This Week: Is It a Good Pick? - InvestorsObserver
Tue, 07 Mar 2023
Should You Buy GT Biopharma Inc (GTBP) Stock After it Has Fallen 5.80% in a Week? - InvestorsObserver
Tue, 28 Feb 2023
GT BIOPHARMA, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K) - Marketscreener.com
Mon, 27 Feb 2023
Where Does GT Biopharma Inc (GTBP) Stock Fall in the Biotechnology Field After It Is Down -20.73% This Week? - InvestorsObserver
Fri, 24 Feb 2023
GT Biopharma to Participate in the H.C. Wainwright Cell Therapy ... - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
36 (M) |
| Shares Float |
27 (M) |
|
% Held by Insiders
|
6.7 (%) |
|
% Held by Institutions
|
19.5 (%) |
|
Shares Short
|
183 (K) |
|
Shares Short P.Month
|
242 (K) |
Stock Financials |
|
EPS
|
-0.96 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.49 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-74 |
|
Return on Equity (ttm)
|
-139.4 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-15 (M) |
|
Levered Free Cash Flow
|
3 (M) |
Stock Valuations |
|
PE Ratio
|
-0.6 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
1.16 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-1.41 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2017-08-20 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
